Is BioVaxys Technology Corp. (BIOV.CN) a Buy, Sell, or Hold?
CNQ : BIOV.CN
BioVaxys Technology Corp.
$0.07 CAD
$0.01 (16.67%)
- Volume
- 13.47K
- Average Volume
- 181.88K
- Market Capitalization
- $2.04M
- P/E Ratio
- -0.59
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.40
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.28
Company Overview
CNQ
James Christopher Passin
Biotechnology
Healthcare
BIOV.CN
3
CA
CAD
Liquidity Metrics
-0.04
0.28
0.28
0.00
0.00
Sales & Valuation
-$
0.00
-0.56
-1.04
-0.07
Profitability
-$0.202
-$3.95M
0.00%
0.00%
121.88%
-237.77%
P/E Metrics
-0.59
0.03
0.03
Analyst Price Target & Rating
0/5
0 Analysts
%
Poll Results
About BioVaxys Technology Corp. (CNQ:BIOV.CN) Stock
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufac ... ture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.
Frequently Asked Questions
-
What is the current BioVaxys Technology Corp. (BIOV.CN) stock price?
-
BioVaxys Technology Corp.(CNQ:BIOV.CN) stock price is $0.07 in the last trading session. During the trading session, BIOV.CN stock reached the peak price of $0.4 while $0.03 was the lowest point it dropped to. The percentage change in BIOV.CN stock occurred in the recent session was 16.67% while the dollar amount for the price change in BIOV.CN stock was $0.01.
-
BIOV.CN's industry and sector of operation?
-
The CNQ listed BIOV.CN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BIOV.CN?
-
David Berd | Co-Founder & Chief Medical Officer
Kenneth E. Kovan | Co-Founder, President & Chief Operating Officer
James Christopher Passin | Co-Founder, Chief Executive Officer, & Director
Christopher Cherry | Chief Financial Officer
| -
How many employees does BIOV.CN have?
-
Number of BIOV.CN employees currently stands at 3. BIOV.CN operates from 905 West Pender Street, Etobicoke, ON V6C 1L6, CA.
-
Link for BIOV.CN official website?
-
Official Website of BIOV.CN is: https://www.biovaxys.com
-
How do I contact BIOV.CN?
-
BIOV.CN could be contacted at phone #646 452 7054 and can also be accessed through its website. BIOV.CN operates from 905 West Pender Street, Etobicoke, ON V6C 1L6, CA.
-
How many shares of BIOV.CN are traded daily?
-
The average number of BIOV.CN shares traded daily for last 3 months was 181.88K.
-
What is the market cap of BIOV.CN currently?
-
The market value of BIOV.CN currently stands at $2.04M with its latest stock price at $0.07